Healthcare services: 60%
Pharmaceutical products: 25%
Medical technology: 15%

United Arab Emirates: 50%
Saudi Arabia: 30%
Kuwait: 10%

Pure Health Holding PJSC generates the majority of its revenues from healthcare services, followed by pharmaceutical products and medical technology. The company's largest market is the United Arab Emirates, accounting for half of the revenue. Saudi Arabia and Kuwait are also significant markets, together accounting for 40% of the revenues. This distribution demonstrates the company's strong regional presence in the Middle East.

Production Sites: United Arab Emirates, Saudi Arabia

Pure Health Holding PJSC is a leading healthcare company headquartered in the United Arab Emirates. The company mainly produces its healthcare products in the United Arab Emirates and has recently expanded its production capacity through new facilities in Saudi Arabia.

This strategic expansion allows Pure Health to strengthen its market presence in the Middle East and respond more efficiently to the growing demand in the region.

Revenue Growth: Estimated 10-12% annually (2025-2027)

Pure Health Holding PJSC pursues a growth strategy focusing on expanding into new markets and diversifying its service offerings. The company plans to strengthen its presence in the Middle East and North Africa by forming strategic partnerships with local healthcare providers.

Additionally, Pure Health is investing in technological innovations to digitize its services and enhance efficiency. This includes expanding telemedicine services and implementing AI-based solutions to improve patient care.

Another key focus is on acquiring companies that offer complementary services to expand the existing portfolio and leverage synergies. This strategy aims not only to promote revenue growth but also to solidify Pure Health's market position as a leading healthcare provider in the region.

Commodities/Materials: Pharmaceutical active ingredients, packaging materials, medical device components

Countries of origin: India, China, Germany, USA

Pure Health Holding PJSC imports a variety of commodities and materials necessary for the production and distribution of their health products. These include pharmaceutical active ingredients, primarily sourced from India and China, as these countries are leading in the production of generic drugs and active ingredients.

Packaging materials and medical device components are often imported from Germany and the USA, as these countries are known for their high-quality production standards and technological innovations. These imports are crucial for maintaining the product quality and international competitiveness of Pure Health Holding.

Market Share: 25% (2025, estimated)
EBITDA Margin: 18% (2024)
R&D Expenses: 5% of revenue (2024)

Pure Health Holding PJSC has a significant competitive advantage in the healthcare industry, especially in the Middle East. The company holds an estimated market share of 25%, indicating its strong presence and trust in its services.

The EBITDA margin of 18% shows that Pure Health operates efficiently and is able to generate solid profits. This is an indicator of the company's ability to control costs while providing high-quality services.

Another important aspect is the investment in research and development, which accounts for about 5% of revenue. These investments enable Pure Health to develop innovative solutions and differentiate itself from competitors. Combined with a strong market position and operational efficiency, this provides the company with a sustainable competitive advantage.

Institutional Investor Share: Estimated 60% (2025)
Insider Buys/Sells: No specific data available (2025)

The institutional investor share in Pure Health Holding PJSC is estimated to be around 60%. This is typical for large publicly traded companies where institutional investors such as pension funds, investment funds, and insurance companies hold significant stakes.

There is currently no specific data available on insider buys or sells. Such transactions are often disclosed in quarterly reports or special company announcements. It would be advisable to review the latest financial reports or regulatory filings to obtain detailed information.

Market share of Pure Health Holding PJSC: 12% (2025, estimated)

Top competitors and their market shares:

1. Mubadala Health: 15%
2. NMC Health: 14%
3. Cleveland Clinic Abu Dhabi: 10%
4. Mediclinic Middle East: 9%
5. Saudi German Hospital Group: 8%
6. Al Zahra Hospital: 7%
7. Burjeel Holdings: 6%
8. Aster DM Healthcare: 5%
9. Thumbay Hospital: 4%
10. Zulekha Healthcare Group: 3%

Moat of Pure Health Holding PJSC:

Pure Health Holding PJSC has a moderate moat, mainly supported by its strong presence in the healthcare services sector and its strategic partnerships. The company benefits from a wide network of clinics and hospitals as well as technological innovations in healthcare that make its services more efficient and patient-oriented.

In comparison to its competitors, Mubadala Health has a stronger moat due to extensive financial resources and a diversified investment strategy in the healthcare sector. Despite its past challenges, NMC Health has also built a solid moat through broad geographical presence and a versatile range of services.

In summary, Pure Health Holding PJSC operates in a competitive market where some competitors have stronger moats. Nevertheless, the company remains competitive through its innovation and strategic alliances.

Revenue Growth: 18% (2024)
Profit Growth: 20% (2024)
Market Share in the Healthcare Sector: 12% (2024)

Pure Health Holding PJSC recorded solid revenue growth of 18% in 2024, driven by strong demand for its healthcare services and products. The company increased its market share in the healthcare sector to 12%, indicating successful expansion and strategic acquisitions.

The 20% profit growth in 2024 suggests that Pure Health has efficiently managed its costs and improved its margins. This positive development is supported by investments in innovative technologies and the expansion of its service portfolio.

Given these growth rates and strategic positioning in the healthcare sector, Pure Health could present an attractive investment opportunity. However, investors should also consider the company's long-term plans and potential risks, such as regulatory changes and market volatility.

Dividend Yield: 3.5% (2025, estimated)

Dividend History: Regular since 2023

Pure Health Holding PJSC started distributing dividends in 2023. The dividend yield is estimated to be around 3.5% for 2025. This suggests that the company follows a policy of regular payouts, indicating a certain level of reliability.

However, the reliability of dividend payments heavily depends on the financial stability and future earnings of the company. Since Pure Health Holding operates in a high-growth sector, dividends could continue to increase in the coming years as long as the company remains profitable and strengthens its market position.